FinnCap reissued their corporate rating on shares of Avacta Group (LON:AVCT) in a report released on Monday. FinnCap currently has a GBX 200 ($2.86) price target on the biotechnology company’s stock.
Shares of AVCT opened at GBX 31.85 ($0.46) on Monday. Avacta Group has a 12 month low of GBX 40 ($0.57) and a 12 month high of GBX 98 ($1.40).
In other Avacta Group news, insider Alastair Smith acquired 35,800 shares of the company’s stock in a transaction on Tuesday, March 13th. The shares were bought at an average cost of GBX 42 ($0.60) per share, with a total value of £15,036 ($21,529.21).
ILLEGAL ACTIVITY NOTICE: This article was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.dispatchtribunal.com/2018/04/17/avacta-groups-avct-corporate-rating-reiterated-at-finncap.html.
About Avacta Group
Avacta Group plc is a biotechnology company. Avacta’s focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Affimer technology has been designed to address performance limitations of antibodies.
Receive News & Ratings for Avacta Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avacta Group and related companies with MarketBeat.com's FREE daily email newsletter.